Close Menu

NEW YORK (GenomeWeb) – Goldfinch Bio announced its launch today with $55 million in Series A financing from Third Rock Ventures.

The firm said that it will use a patient database to collect and integrate genomic and phenotypic data to inform drug development. "Goldfinch will focus on actionable targets for intervention and develop precision therapies for genetically stratified patient groups," the firm noted in a statement, adding it would initially go after orphan indications with a known genetic component, such as focal segmental glomerulosclerosis and polycystic kidney disease.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Three US lawmakers call on the Trump Administration to end its program to collect DNA from detained migrants, the Hill reports.

Soccer players who head the ball a lot and who have a certain APOE allele may be more likely to have memory problems, according to HealthDay.

Researchers in the US have developed a promising candidate vaccine against African swine fever, according to Bloomberg News.

In Cell this week: a quantitative proteomic atlas based on the Cancer Cell Line Encyclopedia, gene regulation and differentiation in Toxoplasma gondii, and more.